-
Mumbai – Piramal Enterprises Limited (“Piramal,” NSE: PEL, BSE: 500302) announced that its wholly owned Critical Care subsidiary in the UK has completed its acquisition of a portfolio of drugs for spasticity and pain management from Mallinckrodt LLC (“Mallinckrodt”).
The portfolio acquired includes Gablofen® (baclofen), a severe spasticity management product, which is currently marketed in the United States, and two pain management products, which are currently under development. Gablofen® has also been approved for launch in eight European markets. Gablofen® is the only intrathecal baclofen drug available in vials and pre-filled syringes, which are preferred by users over the competing products available in ampoules. The pain management drugs under development are also for intrathecal administration.
For further information on the financials, please visit our website: www.piramal.com:
-
Pharmacy staff optimization solution to be developed by Belfast-based big data analytics firm
Belfast, March 31, 2017– ANALYTICS ENGINES have won an SBRI (Small Business Research Initiative) competition to develop and deliver a staff optimization tool to streamline hospital pharmacy operations and ensure patient safety around medicines reconciliation. -
Test Press Release
10 Aug 2017Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam blandit metus ac mauris pellentesque convallis. Phasellus sit amet ipsum augue. Praesent molestie neque sollicitudin, laoreet ex vel, fring ... -
ANALYTICS ENGINES SUCCESSFULLY COMPLETE SBRI PHASE I
Belfast, September 29, 2017– The Small Business Research Initiative for Medicines Optimisation launched by the Department of Health (DoH) and Department for Economy (DfE) in Northern Ireland have approved PRECISION for Pharmacy for deployment at Western Health NHS Trust.
-
The potential acquisition is in line with the Group's strategy to boost growth in the healthcare businesses, both organically and inorganically
October 10, 2016, Mumbai: Piramal Enterprises (NSE: PEL, BSE: 500302) announced that its wholly owned Critical Care subsidiary in the UK has entered into an agreement to acquire five anesthesia and pain management injectable products from Janssen Pharmaceutica NV. The products to be acquired are five injectable versions of well-established Janssen brands, Sublimaze (fentanyl citrate), Sufenta (sufentanil citrate), Rapifen (alfentanil hydrochloride), Dipidolor (piritramide), and Hypnomidate (etomidate) (the “Products”).
Piramal has agreed to acquire the brand names and all related IP as associated with the Products, including the know-how to make both the active pharmaceutical ingredients (“API”) and the finished dosage forms of the Products. The Products are currently marketed in over 50 countries.
For further information on the financials, please visit our website: www.piramal.com
-
Mistura Informatics Limited® was launched in 2011 by Professor Steve Bazire MBE and Dawn Price, both highly revered throughout the world of Pharmacy. Their main aim was to develop and deliver a wide r ...
-
CLIQ secures QE Hospital Birmingham
03 Jan 2018Abloy UK and leading medical equipment manufacturer Bristol Maid have supplied the Queen Elizabeth (QE) Hospital Birmingham with over 1,400 keys and 1,600 locks, fitting PROTEC2 CLIQ® and Traka21 advanced key management systems to improve the security of medicines.
-
Abloy UK Secures Spire Manchester Hospital
05 Jan 2018Abloy UK have supplied Spire Manchester Hospital with PROTEC2 CLIQ® and Traka 21 advanced key management systems to improve the security of medicines and increase nursing efficiency.
-
DMU to help deliver new post-registration pharmacist training to strengthen pharmacy workforce
25 Jan 2018De Montfort University Leicester (DMU) is proud to announce that it will partner with the NHS to deliver masters-level training for qualified post-registration community pharmacists to make the most of their clinical skills.
-
The Tick Twister ClipBox
08 Feb 2018The unique and ingenious Tick Twister tick removers are now offered with a small storage box: the new ClipBox!
-
Following the recent launch of the Safer Pharmacies Charter, PDA (The Pharmacists’ Defence Association) are calling on pharmacists to share their experience of safety in the workplace.
The Safer Pharmacies Survey addresses the key areas outlined in the Safer Pharmacies Charter. With the findings, PDA aim to persuade the government, regulators and employers to improve the working environment for pharmacists, which will in turn improve patient safety. -
BOPA Advanced Clinical Update Course in Oncology
21 Feb 2018REGISTER NOW! Limited Places Available
The Advance Clinical Update Course will cover research design, statistics and evaluation of oncology literature, immunotherapy and targeted therapeutics, biosimilars use in practice and clinical updates in haematology as well as clinical updates on solid tumours.
The sessions will be delivered by Consultants, Specialist Cancer Pharmacists and experts from the Royal Marsden Hospital in London.
29 Results
.jpg-1.png)
.jpg-1.png)
